Literature DB >> 28082342

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.

Francesco Zaja1, Simone Ferrero2, Caterina Stelitano3, Angela Ferrari4, Flavia Salvi5, Annalisa Arcari6, Gerardo Musuraca7, Barbara Botto8, Michele Spina9, Claudia Cellini10, Caterina Patti11, Anna M Liberati12, Claudia Minotto13, Stefano A Pileri14, Manuela Ceccarelli15, Stefano Volpetti16, Antonella Ferranti17, Daniela Drandi2, Elisa Montechiarello3, Marco Ladetto18, James Carmichael19, Renato Fanin16.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28082342      PMCID： PMC5477625          DOI： 10.3324/haematol.2016.154211

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Mats Jerkeman; Riikka Räty; Niels S Andersen; Lone B Pedersen; Mikael Eriksson; Marie Nordström; Eva Kimby; Hans Bentzen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Br J Haematol       Date:  2012-05-29       Impact factor: 6.998

2.  Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

Authors:  Daniela Drandi; Lenka Kubiczkova-Besse; Simone Ferrero; Nadia Dani; Roberto Passera; Barbara Mantoan; Manuela Gambella; Luigia Monitillo; Elona Saraci; Paola Ghione; Elisa Genuardi; Daniela Barbero; Paola Omedè; Davide Barberio; Roman Hajek; Umberto Vitolo; Antonio Palumbo; Sergio Cortelazzo; Mario Boccadoro; Giorgio Inghirami; Marco Ladetto
Journal:  J Mol Diagn       Date:  2015-08-28       Impact factor: 5.568

3.  Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.

Authors:  Francesco Zaja; Stefano De Luca; Umberto Vitolo; Lorella Orsucci; Alessandro Levis; Flavia Salvi; Chiara Rusconi; Erika Ravelli; Alessandra Tucci; Chiara Bottelli; Monica Balzarotti; Ercole Brusamolino; Maurizio Bonfichi; Stefano A Pileri; Elena Sabattini; Stefano Volpetti; Chiara Monagheddu; Angelo Vacca; Roberto Ria; Renato Fanin
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

Authors:  Marek Trněný; Thierry Lamy; Jan Walewski; David Belada; Jiri Mayer; John Radford; Wojciech Jurczak; Franck Morschhauser; Julia Alexeeva; Simon Rule; Boris Afanasyev; Kamil Kaplanov; Antoine Thyss; Alexej Kuzmin; Sergey Voloshin; Kazimierz Kuliczkowski; Agnieszka Giza; Noel Milpied; Caterina Stelitano; Reinhard Marks; Lorenz Trümper; Tsvetan Biyukov; Meera Patturajan; Marie-Laure Casadebaig Bravo; Luca Arcaini
Journal:  Lancet Oncol       Date:  2016-02-16       Impact factor: 41.316

6.  Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

Authors:  Marco Ladetto; Michele Magni; Gloria Pagliano; Federica De Marco; Daniela Drandi; Irene Ricca; Monica Astolfi; Paola Matteucci; Anna Guidetti; Barbara Mantoan; Chiara Lobetti Bodoni; Manuela Zanni; Mario Boccadoro; Alessandro M Gianni; Corrado Tarella
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

7.  Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Authors:  K Sue Robinson; Michael E Williams; Richard H van der Jagt; Philip Cohen; Jordan A Herst; Anil Tulpule; Lee S Schwartzberg; Bernard Lemieux; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

8.  Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.

Authors:  Michael L Wang; Hun Lee; Hubert Chuang; Nicolaus Wagner-Bartak; Frederick Hagemeister; Jason Westin; Luis Fayad; Felipe Samaniego; Francesco Turturro; Yasuhiro Oki; Wendy Chen; Maria Badillo; Krystle Nomie; Maria DeLa Rosa; Donglu Zhao; Laura Lam; Alicia Addison; Hui Zhang; Ken H Young; Shaoying Li; David Santos; L Jeffrey Medeiros; Richard Champlin; Jorge Romaguera; Leo Zhang
Journal:  Lancet Oncol       Date:  2015-11-28       Impact factor: 41.316

9.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.

Authors:  P L Zinzani; J M Vose; M S Czuczman; C B Reeder; C Haioun; J Polikoff; H Tilly; L Zhang; K Prandi; J Li; T E Witzig
Journal:  Ann Oncol       Date:  2013-09-12       Impact factor: 32.976
View more
  7 in total

1.  Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?

Authors:  Simone Ferrero; Martin Dreyling
Journal:  Haematologica       Date:  2017-07       Impact factor: 9.941

Review 2.  Management of Older Adults with Mantle Cell Lymphoma.

Authors:  Jason T Romancik; Jonathon B Cohen
Journal:  Drugs Aging       Date:  2020-07       Impact factor: 3.923

Review 3.  Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.

Authors:  Michael J Buege; Anita Kumar; Brianne N Dixon; Laura A Tang; Terry Pak; Jennifer Orozco; Tim J Peterson; Kathryn T Maples
Journal:  Ann Pharmacother       Date:  2020-02-20       Impact factor: 3.154

Review 4.  IMiDs New and Old.

Authors:  Samuel Yamshon; Jia Ruan
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

5.  Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.

Authors:  Jia Ruan; Peter Martin; Paul Christos; Leandro Cerchietti; Wayne Tam; Bijal Shah; Stephen J Schuster; Amelyn Rodriguez; David Hyman; Maria Nieves Calvo-Vidal; Sonali M Smith; Jakub Svoboda; Richard R Furman; Morton Coleman; John P Leonard
Journal:  Blood       Date:  2018-09-04       Impact factor: 22.113

6.  Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.

Authors:  Samuel Yamshon; Paul J Christos; Michelle Demetres; Hoda Hammad; John P Leonard; Jia Ruan
Journal:  Blood Adv       Date:  2018-06-26

7.  Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma.

Authors:  Georg Hess; Karola Wagner; Ulrich Keller; Paul La Rosee; Johannes Atta; Kai Hübel; Christian Lerchenmueller; Daniel Schoendube; Mathias Witzens-Harig; Christian Ruckes; Christoph Medler; Christina van Oordt; Wolfram Klapper; Matthias Theobald; Martin Dreyling
Journal:  Hemasphere       Date:  2020-06-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.